On the sharp pullback, we are looking for potential buys.
We will be ready to commit new funds on the next market pullback.
We maintain our Two rating ahead of tonight's results.
But we're sticking with TherapeuticsMD.
The prudent move is to pare names that have rallied so far in such a short time.
Whiting Petroleum's move costly to investors.
We think the selloff on preannounced lower results is overdone and have faith in company management.
We expect the company to continue its streak of raising the quarterly payout.
Shares fall on a shareholder's challenge.
We'll take something off the table of TherapeuticsMD and add it to Sonus.